Friday, 16 October 2026European Markets

AFFLUENT MEDICAL Stock Went Up By Over 11% So Far Today

Loading stream...

(vianews) - shares of affluent medical (cac 40: afme.pa) jumped by a staggering 11.11% to €1.60 at 13:42 est on thursday, after three successive sessions in a row of losses. cac 40 is dropping 0.04% to €7,231.18, after three successive sessions in a row of losses. this seems, at the moment, a somewhat negative trend exchanging session today.

affluent medical's last close was €1.48, 70.04% under its 52-week high of €4.94.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.987.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -35.51%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, affluent medical's stock is considered to be overbought (>=80).

more news about affluent medical (afme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com